{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DEN+45+mg",
    "query": {
      "intervention": "DEN 45 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T18:22:32.161Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02831764",
      "title": "An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine (3TC)",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 722,
      "start_date": "2016-07-18",
      "completion_date": "2022-06-29",
      "has_results": true,
      "last_update_posted_date": "2023-12-07",
      "last_synced_at": "2026-09-04T18:22:32.161Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Leandro",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02831764"
    },
    {
      "nct_id": "NCT00242203",
      "title": "Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Zometa",
          "type": "DRUG"
        },
        {
          "name": "Epirubicin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "External beam radiation",
          "type": "RADIATION"
        },
        {
          "name": "Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2002-10",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2013-08-13",
      "last_synced_at": "2026-09-04T18:22:32.161Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00242203"
    },
    {
      "nct_id": "NCT05303636",
      "title": "LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Change in Bone Mineral Density",
        "Bone Loss"
      ],
      "interventions": [
        {
          "name": "drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insud Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 45 Years · Female only"
      },
      "enrollment_count": 1536,
      "start_date": "2022-03-28",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-09-04T18:22:32.161Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • Boynton Beach, Florida + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05303636"
    },
    {
      "nct_id": "NCT01562899",
      "title": "A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Adenocarcinoma",
        "BRAF Mutated Melanoma"
      ],
      "interventions": [
        {
          "name": "MEK162",
          "type": "DRUG"
        },
        {
          "name": "AMG 479",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2012-08-27",
      "completion_date": "2015-04-01",
      "has_results": false,
      "last_update_posted_date": "2020-12-10",
      "last_synced_at": "2026-09-04T18:22:32.161Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01562899"
    },
    {
      "nct_id": "NCT00111800",
      "title": "A New Oral Treatment For Type II Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "DEN 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "DEN 7.5 mg",
          "type": "DRUG"
        },
        {
          "name": "DEN 15 mg",
          "type": "DRUG"
        },
        {
          "name": "DEN 30 mg",
          "type": "DRUG"
        },
        {
          "name": "DEN 45 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 375,
      "start_date": "2005-04-28",
      "completion_date": "2006-07-21",
      "has_results": true,
      "last_update_posted_date": "2018-03-21",
      "last_synced_at": "2026-09-04T18:22:32.161Z",
      "location_count": 36,
      "location_summary": "Long Beach, California • Pasadena, California • Denver, Colorado + 32 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00111800"
    },
    {
      "nct_id": "NCT05461573",
      "title": "Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Contraception",
        "Change in Bone Mineral Density"
      ],
      "interventions": [
        {
          "name": "Drospirenone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insud Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 45 Years · Female only"
      },
      "enrollment_count": 1542,
      "start_date": "2022-08-02",
      "completion_date": "2025-05-27",
      "has_results": false,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-09-04T18:22:32.161Z",
      "location_count": 46,
      "location_summary": "Alabaster, Alabama • Birmingham, Alabama • Tucson, Arizona + 36 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05461573"
    },
    {
      "nct_id": "NCT01156597",
      "title": "Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "35 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2008-04",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2014-11-21",
      "last_synced_at": "2026-09-04T18:22:32.161Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01156597"
    },
    {
      "nct_id": "NCT01135394",
      "title": "Pharmacogenomics of Thiazolidinediones",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "35 Years to 64 Years"
      },
      "enrollment_count": 114,
      "start_date": "2009-03",
      "completion_date": "2018-05-31",
      "has_results": true,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-09-04T18:22:32.161Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01135394"
    },
    {
      "nct_id": "NCT01966809",
      "title": "Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Tumor, Recurrent"
      ],
      "interventions": [
        {
          "name": "Photofrin photodynamic therapy.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harry T Whelan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2015-06",
      "completion_date": "2017-12-19",
      "has_results": true,
      "last_update_posted_date": "2019-08-20",
      "last_synced_at": "2026-09-04T18:22:32.161Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01966809"
    },
    {
      "nct_id": "NCT02831673",
      "title": "An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine (3TC)",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 719,
      "start_date": "2016-07-21",
      "completion_date": "2022-08-15",
      "has_results": true,
      "last_update_posted_date": "2023-08-24",
      "last_synced_at": "2026-09-04T18:22:32.161Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02831673"
    }
  ]
}